Literature DB >> 12522135

Anthrax lethal factor proteolysis and inactivation of MAPK kinase.

Arun P Chopra1, Sherrie A Boone, Xudong Liang, Nicholas S Duesbery.   

Abstract

Anthrax lethal toxin produced by the bacterium Bacillus anthracis is the major cause of death in animals infected with anthrax. One component of this toxin, lethal factor (LF), inactivates members of the mitogen-activated protein kinase kinase or MEK family through proteolysis of their NH(2) termini. However, neither the substrate requirements for LF cleavage nor the mechanism by which proteolysis inactivates MEK have been demonstrated. By means of deletion mutant analysis and site-directed mutagenesis, we have identified an LFIR (LF interacting region) in the COOH-terminal kinase domain of MEK1 adjacent to the proline-rich region, which is essential for LF-mediated proteolysis of MEK. Point mutations in this region block proteolysis but do not alter the kinase activity of MEK. Similar mutations in MEK6 also prevent proteolysis, indicating that this region is functionally conserved among MEKs. In addition, NH(2)-terminal proteolysis of MEK1 by LF was found to reduce not only the affinity of MEK1 for its substrate mitogen-activated protein kinase but also its intrinsic kinase activity, indicating that the NH(2)-terminal end of MEK is important not only for substrate interaction but also for catalytic activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12522135     DOI: 10.1074/jbc.M211262200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  MAPping innate immunity.

Authors:  John A T Young; Andrew Dillin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-24       Impact factor: 11.205

2.  Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor.

Authors:  Arpita Agrawal; César Augusto F de Oliveira; Yuhui Cheng; Jennifer A Jacobsen; J Andrew McCammon; Seth M Cohen
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

Review 3.  The Molecular Basis of Toxins' Interactions with Intracellular Signaling via Discrete Portals.

Authors:  Adi Lahiani; Ephraim Yavin; Philip Lazarovici
Journal:  Toxins (Basel)       Date:  2017-03-16       Impact factor: 4.546

4.  Identification of novel anthrax toxin countermeasures using in silico methods.

Authors:  Ting-Lan Chiu; Kimberly M Maize; Elizabeth A Amin
Journal:  Methods Mol Biol       Date:  2013

5.  Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.

Authors:  Randall W Alfano; Stephen H Leppla; Shihui Liu; Thomas H Bugge; Janelle M Ortiz; Terry C Lairmore; Nicholas S Duesbery; Ian C Mitchell; Fiemu Nwariaku; Arthur E Frankel
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

6.  Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening.

Authors:  Ludovic Bannwarth; Allison B Goldberg; Catherine Chen; Benjamin E Turk
Journal:  Chem Biol       Date:  2012-07-27

7.  Highly predictive support vector machine (SVM) models for anthrax toxin lethal factor (LF) inhibitors.

Authors:  Xia Zhang; Elizabeth Ambrose Amin
Journal:  J Mol Graph Model       Date:  2015-11-17       Impact factor: 2.518

8.  Perturbation of mouse retinal vascular morphogenesis by anthrax lethal toxin.

Authors:  Jennifer L Bromberg-White; Elissa Boguslawski; Nicholas S Duesbery
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

Review 9.  Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins.

Authors:  Holger Barth; Klaus Aktories; Michel R Popoff; Bradley G Stiles
Journal:  Microbiol Mol Biol Rev       Date:  2004-09       Impact factor: 11.056

10.  Anthrax lethal toxin induced lysosomal membrane permeabilization and cytosolic cathepsin release is Nlrp1b/Nalp1b-dependent.

Authors:  Kathleen M Averette; Matthew R Pratt; Yanan Yang; Sara Bassilian; Julian P Whitelegge; Joseph A Loo; Tom W Muir; Kenneth A Bradley
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.